3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Renal Cell
13
Sarcoma
10
Neoplasms
10
Breast Neoplasms
8
Neoplasm Metastasis
7
Carcinoma, Non-Small-Cell Lung
5
Ovarian Neoplasms
3
Colorectal Neoplasms
3
Advanced Cancers
3
Thyroid Neoplasms
2
Solid Tumors
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Liver Neoplasms
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Wilms Tumor
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Unspecified Adult Solid Tumor - Protocol Specific
1
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumours
1
Solid Neoplasm
1
Recurrence
1
Osteosarcoma
1
Optic Nerve Glioma
1
Neuroblastoma
1
Lymphoma
1
Interventions
Cyclophosphamide
41
fludarabine
31
Dexamethasone
27
venetoclax
25
Cytarabine
22
Rituximab
16
pembrolizumab
15
fludarabine phosphate
14
Filgrastim
12
Etoposide
12
Lenalidomide
11
Vincristine
10
Gemcitabine
10
Azacitidine
10
pomalidomide
9
Interleukin-2
9
Granulocyte Colony-Stimulating Factor
9
Doxorubicin
9
Calcium Dobesilate
9
carfilzomib
8
Topotecan
8
Nivolumab
8
Methotrexate
8
Everolimus
8
Decitabine
8
Bortezomib
8
Melphalan
7
Cisplatin
7
Vorinostat
6
Injections
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Recurrence
×
pazopanib
×
Clear all
NCT01165385
2014-11-17
PACIFIK
UNICANCER
Phase 1
Completed
35 enrolled